Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 154

    1.

    Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients.

    Sassen A, Rochon J, Wild P, Hartmann A, Hofstaedter F, Schwarz S, Brockhoff G.

    Breast Cancer Res. 2008;10(1):R2. Epub 2008 Jan 8.

    PMID:
    18182100
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.

    Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE.

    Breast Cancer Res. 2009;11(1):R11. Epub 2009 Feb 24.

    PMID:
    19239686
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    3.

    Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer.

    Sassen A, Diermeier-Daucher S, Sieben M, Ortmann O, Hofstaedter F, Schwarz S, Brockhoff G.

    Breast Cancer Res. 2009;11(4):R50. Epub 2009 Jul 22.

    PMID:
    19624808
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    4.

    Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.

    Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM.

    J Pathol. 2003 Jul;200(3):290-7.

    PMID:
    12845624
    [PubMed - indexed for MEDLINE]
    5.

    Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.

    Bartlett JM, Munro A, Cameron DA, Thomas J, Prescott R, Twelves CJ.

    J Clin Oncol. 2008 Nov 1;26(31):5027-35. Epub 2008 Sep 2.

    PMID:
    18768436
    [PubMed - indexed for MEDLINE]
    6.

    The upgraded role of HER3 and HER4 receptors in breast cancer.

    Koutras AK, Fountzilas G, Kalogeras KT, Starakis I, Iconomou G, Kalofonos HP.

    Crit Rev Oncol Hematol. 2010 May;74(2):73-8. Epub 2009 May 30. Review.

    PMID:
    19481955
    [PubMed - indexed for MEDLINE]
    7.

    Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors.

    Steffensen KD, Waldstrøm M, Andersen RF, Olsen DA, Jeppesen U, Knudsen HJ, Brandslund I, Jakobsen A.

    Int J Oncol. 2008 Jul;33(1):195-204.

    PMID:
    18575766
    [PubMed - indexed for MEDLINE]
    8.

    Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.

    Begnami MD, Fukuda E, Fregnani JH, Nonogaki S, Montagnini AL, da Costa WL Jr, Soares FA.

    J Clin Oncol. 2011 Aug 1;29(22):3030-6. Epub 2011 Jun 27.

    PMID:
    21709195
    [PubMed - indexed for MEDLINE]
    9.

    The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients.

    Memon AA, Sorensen BS, Meldgaard P, Fokdal L, Thykjaer T, Nexo E.

    Br J Cancer. 2006 Jun 5;94(11):1703-9.

    PMID:
    16685269
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    10.

    Gene copy numbers of HER family in breast cancer.

    Zaczek A, Wełnicka-Jaśkiewicz M, Bielawski KP, Jaśkiewicz J, Badzio A, Olszewski W, Rhone P, Jassem J.

    J Cancer Res Clin Oncol. 2008 Feb;134(2):271-9. Epub 2007 Jul 28.

    PMID:
    17661082
    [PubMed - indexed for MEDLINE]
    11.

    EGFR (HER) family protein expression and cytogenetics in 219 squamous cell carcinomas of the upper respiratory tract: ERBB2 overexpression independent prediction of poor prognosis.

    Brunner K, Fischer CA, Driemel O, Hartmann A, Brockhoff G, Schwarz S.

    Anal Quant Cytol Histol. 2010 Apr;32(2):78-89.

    PMID:
    20701076
    [PubMed - indexed for MEDLINE]
    12.

    Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.

    Koutras AK, Kalogeras KT, Dimopoulos MA, Wirtz RM, Dafni U, Briasoulis E, Pectasides D, Gogas H, Christodoulou C, Aravantinos G, Zografos G, Timotheadou E, Papakostas P, Linardou H, Razis E, Economopoulos T, Kalofonos HP, Fountzilas G; Hellenic Cooperative Oncology Group (HeCOG).

    Br J Cancer. 2008 Dec 2;99(11):1775-85. Epub 2008 Nov 4.

    PMID:
    18985033
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    13.

    Low expression of HER2 protein in breast cancer is biologically significant.

    Tovey SM, Reeves JR, Stanton P, Ozanne BW, Bartlett JM, Cooke TG.

    J Pathol. 2006 Nov;210(3):358-62.

    PMID:
    16981252
    [PubMed - indexed for MEDLINE]
    14.

    Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling.

    Tovey SM, Witton CJ, Bartlett JM, Stanton PD, Reeves JR, Cooke TG.

    Breast Cancer Res. 2004;6(3):R246-51. Epub 2004 Mar 23.

    PMID:
    15084248
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    15.

    Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.

    Nikolényi A, Sükösd F, Kaizer L, Csörgo E, Vörös A, Uhercsák G, Ormándi K, Lázár G, Thurzó L, Brodowicz T, Kahán Z.

    Oncology. 2011;80(3-4):269-77. Epub 2011 Jul 7.

    PMID:
    21734419
    [PubMed - indexed for MEDLINE]
    16.

    Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.

    Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ.

    Clin Cancer Res. 2005 Mar 15;11(6):2163-8.

    PMID:
    15788662
    [PubMed - indexed for MEDLINE]
    Free Article
    17.

    Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.

    Lyne JC, Melhem MF, Finley GG, Wen D, Liu N, Deng DH, Salup R.

    Cancer J Sci Am. 1997 Jan-Feb;3(1):21-30.

    PMID:
    9072304
    [PubMed - indexed for MEDLINE]
    18.

    EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations.

    Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, Chen B.

    Mod Pathol. 2005 Aug;18(8):1027-33.

    PMID:
    15920544
    [PubMed - indexed for MEDLINE]
    Free Article
    19.

    Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.

    Yonemori K, Tsuta K, Shimizu C, Hatanaka Y, Hirakawa A, Ono M, Kouno T, Katsumata N, Ando M, Tamura K, Hasegawa T, Kinoshita T, Fujiwara Y.

    J Surg Oncol. 2010 Mar 1;101(3):222-7.

    PMID:
    20087905
    [PubMed - indexed for MEDLINE]
    20.

    Comparison of HER-2/neu oncogene amplification detected by fluorescence in situ hybridization in lobular and ductal breast cancer.

    Rosenthal SI, Depowski PL, Sheehan CE, Ross JS.

    Appl Immunohistochem Mol Morphol. 2002 Mar;10(1):40-6.

    PMID:
    11893034
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk